Top-News
Pharmazeutika Belgien

Oxurion News

Aktie
WKN:  A0J30B ISIN:  BE0003846632 US-Symbol:  TBGNF
0,0002 €
+0,00 €
0,00%
17.05.24 21:43:32
Handeln Depot/Watchlist
Aktienanzahl *
49,82 Mio.
Marktkapitalisierung *
9,96 Tsd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 19.06.2022

Ad-hocs

19.10.18 - GlobeNewswire
Oxurion NV Business Update - Q3 2018
Oxurion NV Business Update - Q3 2018 Shareholders' Approval and Launch of Oxurion NV as new Company Name First patient enrolled in Phase 1 study evaluating THR-687, a ...
27.04.18 - GlobeNewswire
ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)
ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME) Press ...
07.09.17 - GlobeNewswire
ThromboGenics Business Update - H1 2017
ThromboGenics Business Update - H1 2017 Press release                                                          7 September, 2017 Regulated Information Good Progress in Advancing Diabetic Eye ...
01.03.16 - GlobeNewswire
ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March in London
ThromboGenics to Host R&D Investor Meeting on Novel Disease-​Modifying Approaches for Diabetic Eye Disease 18 March in London Leuven, 1 March , 2016 - ThromboGenics NV ...
12.11.15 - GlobeNewswire
ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA® for the Treatment of Non-Proliferative Diabetic Retinopathy (CIRCLE)
ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA® for the Treatment of Non-​Proliferative Diabetic ...
26.06.15 - GlobeNewswire
Oncurious NV Appoints Prof Dr Peter Carmeliet as its Chief Scientific Strategy Advisor
Oncurious NV Appoints Prof Dr Peter Carmeliet as its Chief Scientific Strategy Advisor Leuven, June 26, 2015 - Oncurious NV, an oncology company focused on the development of ...
23.04.15 - GlobeNewswire
ThromboGenics Starts Evaluating JETREA® for the Treatment of Retinal Vein Occlusion (RVO)
ThromboGenics Starts Evaluating JETREA® for the Treatment of Retinal Vein Occlusion (RVO) Company receives € 0.6 million research grant from IWT,  the Flemish Agency for ...
22.01.15 - GlobeNewswire
ThromboGenics Appoints Emmanuèle Attout as Independent Non-Executive Director
ThromboGenics Appoints Emmanuèle Attout as Independent Non-​Executive Director Leuven, Belgium - 22 January, 2015 - ThromboGenics NV (Euronext Brussels: THR), an ...

Newssuche

Videos

17.05.24 +14,15%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »